XTL Biopharmaceuticals Announces Shareholder Meeting Outcomes
Company Announcements

XTL Biopharmaceuticals Announces Shareholder Meeting Outcomes

XTL Biopharmaceuticals Ltd. Sponsored ADR (XTLB) has released an update.

XTL Biopharmaceuticals Ltd. successfully held its Annual and Extraordinary General Meeting, with shareholders approving all proposals including the appointment of auditors, re-election of board members, and terms of the acquisition of The Social Proxy Ltd. The company, focusing on developing treatments for Lupus and Sjögren’s Syndrome, is traded on both the Nasdaq and Tel Aviv Stock Exchange and is seeking strategic partnerships for clinical trials while expanding its portfolio.

For further insights into XTLB stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskXTL Biopharmaceuticals Resolves Dispute with Social Proxy
TipRanks Auto-Generated NewsdeskXTL Biopharmaceuticals Faces Financial Dispute After Acquisition
TipRanks Auto-Generated NewsdeskXTL Biopharmaceuticals Expands with AI Company Acquisition
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App